Arecor and Sequel to Co-Develop AT278 With Twiist AID for High-Dose Diabetes Care

Overview

• Arecor signed a co-development agreement with Sequel Med Tech to pair its 500U/mL ultra-rapid insulin candidate AT278 with the FDA-cleared twiist automated insulin delivery system.
• Both companies will contribute up to $1.3 million each to immediate trial-enabling work that includes regulatory interactions, clinical trial batch manufacturing, and compatibility testing.
• The plan is to complete development activities in the first half of 2026 and submit an IND to the FDA, with a clinical study expected to follow in the second half of 2026 if the application is accepted.
• Arecor secured up to $11 million in non-dilutive capital through a royalty financing with Ligand Pharmaceuticals, including $7 million upfront and up to $4 million tied to commercial milestones.
• Sequel’s twiist, powered by Tidepool, directly measures delivered insulin volume using iiSure acoustic sensing and, the company says, can detect occlusions faster than other AID systems, while Arecor positions AT278 as the only ultra-concentrated ultra-rapid insulin in development and both parties signal intent for a broader commercialization partnership.